Vesilute is a Khavinson bioregulator dipeptide consisting of glutamic acid and aspartic acid (ED), developed at the St. Petersburg Institute of Bioregulation and Gerontology. It is specifically designed to support bladder and urinary tract function, with research indicating potential benefits for prostate health in men. Vesilute may help regulate smooth muscle function, enhance tissue blood flow, and support cellular regeneration in urogenital tissues. It is distinct from Vesugen (KED tripeptide), which targets vascular endothelium.